AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23624336 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents (15-17 years)
Number of subjects: 2
Study 23624336 — intervention group
Group type: COMPARATOR
Intervention: Adults (25-30 years)
Number of subjects: 2
Study 21977379 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine patch (9.5 mg/24-h)
Number of subjects: 0
Study 21977379 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine capsules (12 mg/d)
Number of subjects: 0
Study 21977379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19122080 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of normal saline solution at a rate of 5 mL/sec through an 18-gauge needle at the inferomedial location
Number of subjects: 56
Study 19122080 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of normal saline solution at a rate of 5 mL/sec through an 18-gauge needle at the superomedial location
Number of subjects: 56
Study 19122080 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of normal saline solution to diagnose 50% of arthrotomies
Number of subjects: 56
Study 19122080 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of normal saline solution to diagnose 75% of arthrotomies
Number of subjects: 56
Study 19122080 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of normal saline solution to diagnose 90% of arthrotomies
Number of subjects: 56
Study 19122080 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of normal saline solution to diagnose 95% of arthrotomies
Number of subjects: 56
Study 19122080 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of normal saline solution to diagnose 99% of arthrotomies
Number of subjects: 56
Study 17222324 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg at bedtime
Number of subjects: 35
Study 17222324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 15605774 — intervention group
Group type: EXPERIMENTAL
Intervention: Karinat (antioxidant dietary supplement)
Number of subjects: 66
Study 15605774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 11556943 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Minute Preceptor (OMP) intervention, 1‐hour session with lecture, group discussion, and role‐play
Number of subjects: 57
Study 11556943 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 57
Study 11556943 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Minute Preceptor (OMP) intervention
Number of subjects: 57
Study 9786536 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual hyoscyamine sulfate (0.125 mg)
Number of subjects: 54
Study 9786536 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketorolac tromethamine (30 mg)
Number of subjects: 54
Study 7602722 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (Nutrodrip Standard)
Number of subjects: 100
Study 7602722 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet supplemented with 20 g of soluble fiber (partially hydrolyzed guar gum, Sunfiber)
Number of subjects: 100
Study 3048467 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan + TBI
Number of subjects: 63
Study 3048467 — intervention group
Group type: COMPARATOR
Intervention: CY/TBI
Number of subjects: 63
Study 27819483 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-with-movement (MM) intervention (n = 58)
Number of subjects: 165
Study 27819483 — intervention group
Group type: COMPARATOR
Intervention: Music listening (ML) (n = 54)
Number of subjects: 165
Study 27819483 — intervention group
Group type: COMPARATOR
Intervention: Social activity (SA) (n = 53)
Number of subjects: 165
Study 27303746 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan- and triclocarban (TCS)-containing HPCPs
Number of subjects: 0
Study 27303746 — intervention group
Group type: COMPARATOR
Intervention: Non-triclosan/triclocarban (nTCS)-containing HPCPs
Number of subjects: 0
Study 26048955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Number of subjects: 0
Study 26048955 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Sleep
Number of subjects: 0
Study 26048955 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Testing after Sleep Deprivation
Number of subjects: 0
Study 26048955 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Sleep for Finger Motor Responses
Number of subjects: 0
Study 23456214 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning intervention (implementation intention)
Number of subjects: 144
Study 23456214 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneously generated action plans about snacking
Number of subjects: 144
Study 20859301 — intervention group
Group type: EXPERIMENTAL
Intervention: diet (D)
Number of subjects: 157
Study 20859301 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise (E)
Number of subjects: 157
Study 20859301 — intervention group
Group type: EXPERIMENTAL
Intervention: diet and exercise (DE)
Number of subjects: 157
Study 20859301 — intervention group
Group type: COMPARATOR
Intervention: control (C)
Number of subjects: 157
Study 18338278 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS therapy (20 minutes, 15 sessions over 3 weeks)
Number of subjects: 19
Study 18338278 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation (15 sessions over 3 weeks)
Number of subjects: 19
Study 15313089 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape intervention
Number of subjects: 581
Study 15313089 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet control
Number of subjects: 581
Study 11263625 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 123
Study 11263625 — intervention group
Group type: COMPARATOR
Intervention: Accelerated t-PA
Number of subjects: 123
Study 9683949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous teicoplanin (5 patients each at 1 h, 12 h, 24 h pre-operatively, and 24 h and 48 h pre-operatively)
Number of subjects: 25
Study 9683949 — intervention group
Group type: COMPARATOR
Intervention: Topical teicoplanin drops (5 patients, half-hourly for 6 h before vitrectomy)
Number of subjects: 25
Study 7810633 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligopeptides
Number of subjects: 12
Study 7810633 — intervention group
Group type: COMPARATOR
Intervention: Whole casein
Number of subjects: 12
Study 3061441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol and fluocinonide in Lassar's paste
Number of subjects: 24
Study 3061441 — intervention group
Group type: COMPARATOR
Intervention: Dithranol in Lassar's paste
Number of subjects: 24
Study 28155101 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intermittent hypoxia (IH) - 10 sessions over 2 weeks, 70 min per session
Number of subjects: 6
Study 26848765 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein/low carbohydrate diet (diet HP)
Number of subjects: 283
Study 26848765 — intervention group
Group type: COMPARATOR
Intervention: Standard hypocaloric diet (diet S)
Number of subjects: 283
Study 24702251 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine (83 mg for slow acetylators, 182 mg for fast acetylators)
Number of subjects: 12
Study 24702251 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (700 mg every 8 hours)
Number of subjects: 12
Study 21929846 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram or nortriptyline
Number of subjects: 811
Study 21929846 — intervention group
Group type: EXPERIMENTAL
Intervention: citalopram
Number of subjects: 811
Study 20540172 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Supreme
Number of subjects: 99
Study 20540172 — intervention group
Group type: COMPARATOR
Intervention: LMA ProSeal
Number of subjects: 99
Study 17008798 — intervention group
Group type: EXPERIMENTAL
Intervention: Active EECP therapy
Number of subjects: 30
Study 16120091 — intervention group
Group type: EXPERIMENTAL
Intervention: HMR 1031 (20 mg b.i.d.)
Number of subjects: 14
Study 16120091 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 14
Study 11572294 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbide bur #8 round
Number of subjects: 72
Study 11572294 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond bur #801
Number of subjects: 72
Study 11572294 — intervention group
Group type: EXPERIMENTAL
Intervention: KCP 1000 air abrasion unit
Number of subjects: 72
Study 11572294 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicsys Approx.
Number of subjects: 72
Study 11572294 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 72
Study 11572294 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbide bur plus air abrasive
Number of subjects: 72
Study 11572294 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbide bur plus laser
Number of subjects: 72
Study 11572294 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser without etching
Number of subjects: 72
Study 9451475 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin, 20 mg/day
Number of subjects: 49
Study 9451475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 7938368 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training (6 sessions à 90 minutes)
Number of subjects: 27
Study 7938368 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (6 sessions à 90 minutes)
Number of subjects: 27
Study 7938368 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training and hypnosis
Number of subjects: 27
Study 3131256 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat infusion (1.2 g fat/kg B.W./day)
Number of subjects: 0
Study 3131256 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrates alone covering total energy expenditure
Number of subjects: 0
Study 30658676 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Continuous Positive Airway Pressure (NCPAP)
Number of subjects: 141
Study 30658676 — intervention group
Group type: COMPARATOR
Intervention: Heated Humidified High-Flow Nasal Cannula (HHHFNC)
Number of subjects: 141
Study 28600309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulce Digital intervention (up to three motivational, educational, and/or call-to-action text messages per day over 6 months)
Number of subjects: 126
Study 28600309 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 126
Study 28600309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulce Digital intervention
Number of subjects: 126
Study 26749228 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1200 mg, 600 mg 8 hours before and 600 mg 2 hours before anesthesia induction)
Number of subjects: 58
Study 26749228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (talc powder)
Number of subjects: 58
Study 26749228 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1200 mg)
Number of subjects: 58
Study 24255597 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplement (Perfectil® Platinum)
Number of subjects: 80
Study 24255597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 21804509 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levofloxacin 750mg once daily for 7 days
Number of subjects: 100
Study 21804509 — intervention group
Group type: COMPARATOR
Intervention: Injectable levofloxacin 500mg once daily for 7 days
Number of subjects: 100
Study 19366978 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 105
Study 19366978 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 105
Study 16452280 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (medication and counseling for up to 12 months)
Number of subjects: 1602
Study 16452280 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1602
Study 16452280 — intervention group
Group type: EXPERIMENTAL
Intervention: Receipt of preferred treatment
Number of subjects: 1602
Study 15265539 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress ('public speech')
Number of subjects: 12
Study 15265539 — intervention group
Group type: COMPARATOR
Intervention: Good oral hygiene
Number of subjects: 12
Study 15265539 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque accumulation
Number of subjects: 12
Study 11737924 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT-driven extubation protocol
Number of subjects: 0
Study 11737924 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 0
Study 9002119 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin alone (Group I)
Number of subjects: 44
Study 9002119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus inhaled amikacin (Group II)
Number of subjects: 44
Study 9002119 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (both groups)
Number of subjects: 44
Study 8431048 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin and thymopentin (group A)
Number of subjects: 60
Study 8431048 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (group A)
Number of subjects: 60
Study 8431048 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (added to indomethacin in group A)
Number of subjects: 60
Study 8431048 — intervention group
Group type: COMPARATOR
Intervention: Control (group C)
Number of subjects: 60
Study 31399540 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined perineural dexmedetomidine (1 µg/kg) and dexamethasone (10 mg) in 2 mL (RSM group)
Number of subjects: 80
Study 31399540 — intervention group
Group type: COMPARATOR
Intervention: Perineural dexamethasone (10 mg) in 2 mL (RS group)
Number of subjects: 80
Study 31399540 — intervention group
Group type: COMPARATOR
Intervention: Perineural dexmedetomidine (1 µg/kg) in 2 mL (RM group)
Number of subjects: 80
Study 31399540 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine with normal saline (R group)
Number of subjects: 80
Study 30671061 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe injury patients (burn, trauma, septic shock)
Number of subjects: 313
Study 30671061 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (HV)
Number of subjects: 313
Study 26466937 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (48-week treatment)
Number of subjects: 885
Study 24706729 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention to promote longer duration and exclusivity of breastfeeding (n = 16 sites)
Number of subjects: 13000
Study 24706729 — intervention group
Group type: COMPARATOR
Intervention: Control intervention of continuing usual care (n = 15 sites)
Number of subjects: 13000
Study 24706729 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention
Number of subjects: 13000
Study 22572234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bolus injection of 0.375% ropivacaine into intrapleural space (IPA group, n = 20)
Number of subjects: 40
Study 22572234 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural analgesia with 0.375% ropivacaine (TEA group, n = 20)
Number of subjects: 40
Study 19908105 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg x kg(‐1)
Number of subjects: 120
Study 19908105 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine-priming
Number of subjects: 120
Study 19908105 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming
Number of subjects: 120
Study 19908105 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 120
Study 17929018 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 100
Study 17929018 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B (L-AmB)
Number of subjects: 100
Study 17053894 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread meal before itraconazole administration
Number of subjects: 144
Study 17053894 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice meal before itraconazole administration
Number of subjects: 144
Study 12514652 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without angina
Number of subjects: 553
Study 12514652 — intervention group
Group type: COMPARATOR
Intervention: Patients with recurrent angina
Number of subjects: 553
Study 10376571 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene, 60 mg, 2 tablets daily
Number of subjects: 7705
Study 10376571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study 8629721 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment (specific details not provided)
Number of subjects: 0
Study 8629721 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (specific details not provided)
Number of subjects: 0
Study 1381330 — intervention group
Group type: EXPERIMENTAL
Intervention: Combaren (diclofenac-Na 50 mg + codeine phosphate 50 mg)
Number of subjects: 184
Study 1381330 — intervention group
Group type: COMPARATOR
Intervention: diclofenac-Na 50 mg (Voltaren 50)
Number of subjects: 184
Study 6421009 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg ISDN (acute administration)
Number of subjects: 0
Study 6421009 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg ISDN (chronic treatment, four doses daily)
Number of subjects: 0
Study 6421009 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ISDN (acute administration)
Number of subjects: 0
Study 6421009 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ISDN (long-term treatment, twice daily)
Number of subjects: 0
Study 6421009 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg NTG (sublingual during treatment with 40 mg ISDN)
Number of subjects: 0
Study 31011758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib 250 mg, 500 mg, or 1000 mg
Number of subjects: 0
Study 31011758 — intervention group
Group type: COMPARATOR
Intervention: Ivosidenib 500 mg with high-fat meal
Number of subjects: 0
Study 31011758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib 250 mg with itraconazole 200 mg once daily
Number of subjects: 0
Study 30248052 — intervention group
Group type: COMPARATOR
Intervention: Antipsychotics, citalopram, or placebo (duration: up to 36 weeks, mean 252±52 days)
Number of subjects: 421
Study 25023458 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic apheresis with Albutein® 5%
Number of subjects: 0
Study 25023458 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with therapeutic apheresis and haemopheresis with Albutein® and intravenous immunoglobulin (Flebogamma® DIF)
Number of subjects: 0
Study 24057428 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body endurance training (ET), 10 sessions
Number of subjects: 11
Study 24057428 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON), standard individualized MS rehabilitation, n = 5
Number of subjects: 11
Study 23405791 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Xuanju Capsule (CXC) at 3 g tid plus sildenafil at 50 mg an hour before sexual activity
Number of subjects: 36
Study 23405791 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil alone at 100 mg an hour before sexual activity
Number of subjects: 36
Study 19093205 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of Taiproton (generic lansoprazole)
Number of subjects: 8
Study 19093205 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of Tapizol (generic lansoprazole)
Number of subjects: 8
Study 19093205 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of Lansoral (generic lansoprazole)
Number of subjects: 8
Study 19093205 — intervention group
Group type: COMPARATOR
Intervention: Original lansoprazole (Takepron)
Number of subjects: 8
Study 17893038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 60
Study 17893038 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 60
Study 17893038 — intervention group
Group type: COMPARATOR
Intervention: Control (normocholesterolemic patients)
Number of subjects: 60
Study 15108115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraabdominal pressure (IAP) raised from 12 to 20 mmHg
Number of subjects: 22
Study 15108115 — intervention group
Group type: COMPARATOR
Intervention: Intraabdominal pressure (IAP) at 12 mmHg
Number of subjects: 22
Study 11672828 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 microg/kg rHuIL‐12
Number of subjects: 106
Study 11672828 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 microg/kg rHuIL‐12
Number of subjects: 106
Study 11672828 — intervention group
Group type: COMPARATOR
Intervention: 0.03 microg/kg rHuIL‐12
Number of subjects: 106
Study 11672828 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10 microg/kg rHuIL‐12
Number of subjects: 106
Study 11672828 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microg/kg rHuIL‐12
Number of subjects: 106
Study 9594519 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural injection of buprenorphine (0.2 mg) with 0.25% bupivacaine (40 ml) for 24 hours (Group A)
Number of subjects: 104
Study 9594519 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of buprenorphine (0.2 mg) followed by continuous injection of buprenorphine (0.2 mg) with 0.25% bupivacaine (40 ml) for 24 hours (Group B)
Number of subjects: 104
Study 9594519 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of buprenorphine (0.2 mg) followed by continuous buprenorphine infusion with normal saline (Group C)
Number of subjects: 104
Study 9594519 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural injection of buprenorphine (Group C)
Number of subjects: 104
Study 8207739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 42-5892 (100 mg once daily orally)
Number of subjects: 25
Study 8207739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 42-5892 (10 mg intravenously)
Number of subjects: 25
Study 8207739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 2530925 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 micrograms fentanyl with 12 ml of 0.25% plain bupivacaine
Number of subjects: 124
Study 2530925 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms sufentanil with 12 ml of 0.25% plain bupivacaine
Number of subjects: 124
Study 2530925 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline with 12 ml of 0.25% plain bupivacaine)
Number of subjects: 124
Study 2530925 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 micrograms fentanyl
Number of subjects: 124